Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHL TelemedicineSHMLF 54 3-Year EPS without NRI Growth Rate is 7.10% as of Dec. 2025. GuruFocus rates SHMLF with a GF Score™ of 54/100 and a GF Value™ of $11.97. The stock has 5 warning signs investors should review. Among 506 Healthcare Providers & Services companies, SHL Telemedicine ranks worse than 56.52% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 7.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of SHL Telemedicine was 23.50% per year. The lowest was -105.90% per year. And the median was -32.35% per year.
SHL Telemedicine (OTCPK:SHMLF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
SHL Telemedicine 3-Year EPS without NRI Growth Rate Related Terms
SHMLF vs VEEV, BTSG, HQY: 3-Year EPS without NRI Growth Rate Comparison
For the Health Information Services subindustry, SHL Telemedicine's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SHL Telemedicine 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, SHL Telemedicine's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where SHL Telemedicine's 3-Year EPS without NRI Growth Rate falls into.
SHL Telemedicine 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 7.10% mean?
SHL Telemedicine (SHMLF) has a 3-Year EPS without NRI Growth Rate of 7.10% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for SHL Telemedicine and its competitors. According to the industry distribution chart, SHL Telemedicine ranks #286 out of 506 companies in the Healthcare Providers & Services industry, placing it in the top 56.5%.
Is SHL Telemedicine's 3-Year EPS without NRI Growth Rate too high?
SHL Telemedicine's current 3-Year EPS without NRI Growth Rate is 7.10%. The Healthcare Providers & Services industry median 3-Year EPS without NRI Growth Rate is 11.05. SHL Telemedicine's value of 7.10% is 35.7% below this industry median. Based on the distribution chart, SHL Telemedicine ranks #286 out of 506 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, SHL Telemedicine has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does SHL Telemedicine's 3-Year EPS without NRI Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, SHL Telemedicine ranks #286 out of 506 companies for 3-Year EPS without NRI Growth Rate. This places SHL Telemedicine in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.05. SHL Telemedicine's value of 7.10% is 35.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 11.05, based on 506 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SHL Telemedicine's current 3-Year EPS without NRI Growth Rate of 7.10% is 35.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for SHL Telemedicine and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 11.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SHL Telemedicine's current 3-Year EPS without NRI Growth Rate is 7.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SHL Telemedicine stock overvalued right now?
SHL Telemedicine (SHMLF) has a current 3-Year EPS without NRI Growth Rate of 7.10%. The stock's GF Value™ is $11.97, compared to a current price of $4.84 — trading 59.5% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 7.10% and 35.7% below the Healthcare Providers & Services industry median of 11.05. SHL Telemedicine's overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For SHL Telemedicine (SHMLF), the current 3-Year EPS without NRI Growth Rate is 7.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SHL Telemedicine (SHMLF) Overvalued in 2026?
Based on GuruFocus' analysis, SHL Telemedicine stock appears to be undervalued.
The current stock price of $4.84 is trading 59.5% below its estimated GF Value™ of $11.97.
Key valuation signals for SHMLF:
3-Year EPS without NRI Growth Rate: 7.10%
GF Value™: $11.97 vs. price of $4.84 (59.5% below fair value)
Industry Position: 35.7% below the Healthcare Providers & Services median (#286 of 506)
No single metric tells the full story. See the SHMLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SHL Telemedicine Ltd develops and markets personal telemedicine solutions. The company consists of the transmission of medical data by an individual, from a remote location to a medical call center, through telecommunication networks. The company provides healthcare professional solutions to patients suffering from congestive heart failure, chronic obstructive pulmonary disease, and readmission solutions for reducing heart-related readmissions. In addition, consumer solutions include cardiac monitoring services. The company's geographical segments are Israel, Europe, and the rest of the world, out of which majority of revenue comes from Israel.
54GF Score
Get the complete analysis for SHMLF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHMLF has been successfully added to your 
